{"id":7748,"date":"2026-03-26T08:01:00","date_gmt":"2026-03-26T07:01:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2025\/"},"modified":"2026-03-26T08:01:00","modified_gmt":"2026-03-26T07:01:00","slug":"nanexa-publicerar-arsredovisning-for-2025","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-arsredovisning-for-2025\/","title":{"rendered":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2025"},"content":{"rendered":"
\n

Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2025 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida: <\/strong>https:\/\/www.nanexa.com\/finansiella-rapporter<\/a><\/strong>.<\/strong><\/p>\n

Under \u00e5ret har Nanexa gjort stora framsteg inom NEX-22-projektet, d\u00e4r utvecklingen av m\u00e5nads- och kvartalsformuleringar av semaglutid visat lovande prekliniska resultat under f\u00f6rsta kvartalet 2026. I december tecknades \u00e4ven ett licens- och optionsavtal med Moderna, vilket gav Nanexa en initial betalning p\u00e5 3 MUSD och en m\u00f6jlighet till upp till 500 MUSD i milstolpebetalningar och framtida royaltyint\u00e4kter.<\/p>\n

\u201dAvtalet med Moderna \u00e4r ett genombrott f\u00f6r v\u00e5r aff\u00e4rsstrategi och bekr\u00e4ftar styrkan i v\u00e5r PharmaShell\u00ae-teknologi. Samtidigt har vi tagit viktiga steg inom NEX-22-projektet d\u00e4r vi nu \u00e4ven inkluderat semaglutid och vi ser att projektet har stor marknadspotential,\u201d s\u00e4ger David Westberg, vd p\u00e5 Nanexa.<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 vd, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Bolagets Certified Adviser \u00e4r Tapper Partners AB.<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa introducerar kontroll, precision och m\u00e5ngsidighet till l\u00e4kemedelsformuleringar med hj\u00e4lp av ALD-teknik (Atomic Layer Deposition). F\u00f6retagets patenterade PharmaShell\u00ae-plattform \u00e4r ett unikt drug delivery-system som m\u00f6jligg\u00f6r h\u00f6g drug load vilket ger l\u00e5g injektionsvolym och skapar en ny generation formuleringar, s\u00e5 kallade \u201dsuper generics\u201d som ger st\u00f6rre bekv\u00e4mlighet och minskar kostnaderna vid behandling av allehanda sjukdomstillst\u00e5nd som metabola sjukdomar, t ex typ 2-diabetes och obesitas, hematologi\/onkologi, hj\u00e4rt-k\u00e4rlsjukdomar, psykiatri och m\u00e5nga andra.
Nanexa utvecklar egna l\u00e4kemedelsprodukter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland det senaste licens- och optionsavtalet med Moderna.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Nanexa \u00c5rsredovisning 2025<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2025 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida: https:\/\/www.nanexa.com\/finansiella-rapporter<\/a>.<\/p>\n

Under \u00e5ret har Nanexa gjort stora framsteg inom NEX-22-projektet,<\/p>\n

L\u00e4s mer<\/a><\/p>\n","protected":false},"template":"","class_list":["post-7748","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-annual_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa publicerar \u00e5rsredovisning f\u00f6r 2025 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-arsredovisning-for-2025\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2025 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2025 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida: https:\/\/www.nanexa.com\/finansiella-rapporter. Under \u00e5ret har Nanexa gjort stora framsteg inom NEX-22-projektet,L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-arsredovisning-for-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2025\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2025\\\/\",\"name\":\"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2025 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2026-03-26T07:01:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2025\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2025\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2025 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-arsredovisning-for-2025\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2025 - Nanexa AB","og_description":"Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2025 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida: https:\/\/www.nanexa.com\/finansiella-rapporter. Under \u00e5ret har Nanexa gjort stora framsteg inom NEX-22-projektet,L\u00e4s mer","og_url":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-arsredovisning-for-2025\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-arsredovisning-for-2025\/","url":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-arsredovisning-for-2025\/","name":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2025 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2026-03-26T07:01:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-arsredovisning-for-2025\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-arsredovisning-for-2025\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-arsredovisning-for-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2025"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}